CSI Laboratories has entered into an agreement with Bank of America for a revolving line of capital.
“This credit facility gives CSI laboratories additional liquidity for new infrastructure and growth objectives, including the development of advanced testing initiatives,” said Chris Wicker, CEO of CSI. “It also provides additional financial assurances to our current and new customers that we will be able to quickly scale as needed to meet increased case load and turnaround time demands.”_x000D_
“We at Bank of America believe that CSI Laboratories is well-positioned for continued expansion in a dynamic market space,” said Ben Sullivan, senior relationship manager, Business Banking at Bank of America Merrill Lynch. “Bank of America is excited about providing growth capital to CSI and supporting their mission in cancer diagnostic care.”
The new credit facility will be used by CSI Laboratories for general corporate purposes, including working capital and infrastructure enhancements.
CSI Laboratories was founded in 1997 to provide a more client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals and their patients.
